Cigna Corporation
Cigna Corporation CI Peers
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $300.05 | +1.78% | 80.1B | 16.71 | $17.95 | +1.94% |
| UNH | $285.13 | +1.06% | 258.6B | 11.94 | $23.88 | +2.99% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +2.37% |
| CVS | $61.08 | -0.91% | 77.2B | 14.57 | $4.19 | +4.37% |
| ELV | $281.72 | +1.91% | 63.4B | 11.95 | $23.58 | +2.37% |
| HUM | $231.12 | +3.44% | 27.9B | 16.33 | $14.16 | +1.54% |
| CNC | $27.89 | +1.68% | 13.9B | 4.11 | $6.78 | N/A |
| MOH | $180.64 | +2.38% | 9.8B | 8.72 | $20.70 | N/A |
| OSCR | $14.70 | +7.93% | 3.7B | 36.80 | $0.40 | N/A |
| ALHC | $12.34 | -1.28% | 2.4B | -26.24 | -$0.47 | N/A |
Stock Comparison
CI vs UNH Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, UNH has a market cap of 258.6B. Regarding current trading prices, CI is priced at $300.05, while UNH trades at $285.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas UNH's P/E ratio is 11.94. In terms of profitability, CI's ROE is +0.12%, compared to UNH's ROE of +0.24%. Regarding short-term risk, CI is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CI.
CI vs ANTM Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $300.05, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.12%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs CVS Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, CVS has a market cap of 77.2B. Regarding current trading prices, CI is priced at $300.05, while CVS trades at $61.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas CVS's P/E ratio is 14.57. In terms of profitability, CI's ROE is +0.12%, compared to CVS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.
CI vs ELV Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, ELV has a market cap of 63.4B. Regarding current trading prices, CI is priced at $300.05, while ELV trades at $281.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas ELV's P/E ratio is 11.95. In terms of profitability, CI's ROE is +0.12%, compared to ELV's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs HUM Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, HUM has a market cap of 27.9B. Regarding current trading prices, CI is priced at $300.05, while HUM trades at $231.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas HUM's P/E ratio is 16.33. In terms of profitability, CI's ROE is +0.12%, compared to HUM's ROE of +0.10%. Regarding short-term risk, CI is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs CNC Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, CNC has a market cap of 13.9B. Regarding current trading prices, CI is priced at $300.05, while CNC trades at $27.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas CNC's P/E ratio is 4.11. In terms of profitability, CI's ROE is +0.12%, compared to CNC's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs MOH Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, MOH has a market cap of 9.8B. Regarding current trading prices, CI is priced at $300.05, while MOH trades at $180.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas MOH's P/E ratio is 8.72. In terms of profitability, CI's ROE is +0.12%, compared to MOH's ROE of +0.26%. Regarding short-term risk, CI is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs OSCR Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, OSCR has a market cap of 3.7B. Regarding current trading prices, CI is priced at $300.05, while OSCR trades at $14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas OSCR's P/E ratio is 36.80. In terms of profitability, CI's ROE is +0.12%, compared to OSCR's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs ALHC Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, ALHC has a market cap of 2.4B. Regarding current trading prices, CI is priced at $300.05, while ALHC trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas ALHC's P/E ratio is -26.24. In terms of profitability, CI's ROE is +0.12%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs CLOV Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, CLOV has a market cap of 1.6B. Regarding current trading prices, CI is priced at $300.05, while CLOV trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas CLOV's P/E ratio is -80.50. In terms of profitability, CI's ROE is +0.12%, compared to CLOV's ROE of -0.07%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs BHG Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $300.05, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.12%, compared to BHG's ROE of -0.47%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs BMGL Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, BMGL has a market cap of 41.3M. Regarding current trading prices, CI is priced at $300.05, while BMGL trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas BMGL's P/E ratio is 220.00. In terms of profitability, CI's ROE is +0.12%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, CI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs MRAI Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, MRAI has a market cap of 21.5M. Regarding current trading prices, CI is priced at $300.05, while MRAI trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas MRAI's P/E ratio is -0.49. In terms of profitability, CI's ROE is +0.12%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, CI is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs IVF Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, IVF has a market cap of 7.5M. Regarding current trading prices, CI is priced at $300.05, while IVF trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas IVF's P/E ratio is -0.03. In terms of profitability, CI's ROE is +0.12%, compared to IVF's ROE of -5.72%. Regarding short-term risk, CI is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs NIVF Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, NIVF has a market cap of 2.4M. Regarding current trading prices, CI is priced at $300.05, while NIVF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas NIVF's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.12%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, CI is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CI.
CI vs MGLN Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $300.05, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.12%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.
CI vs GTS Comparison
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 80.1B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $300.05, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 16.71, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.12%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.